The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.

摘要: Background Although guidelines recommend anti-inflammatory therapy for persistent asthma, recent studies suggest that 25% to 35% of patients with asthma may not improve lung function inhaled corticosteroids. Objective To evaluate potential biomarkers predicting short-term (6-week) response corticosteroid subsequent evaluation responders and nonresponders control over a longer interval (16 additional weeks). Methods Eighty-three subjects off steroid were enrolled in this multicenter study. Biomarkers characteristics evaluated as predictors 6-week trial changes FEV 1 methacholine PC 20 . After this, an 4-month control. Results multiple baseline had significant correlations improvements success, the only strong ( r ≥ ± 0.6) albuterol reversibility = 0.83; P /forced vital capacity −0.75; % predicted −0.71; 5% improvement) (≤5%) determined longer-term need steroids. For nonresponders, remained unchanged whether corticosteroids continued or substituted placebo .99). The good maintained if on steroids .007). Conclusion regard improvement predicts long-term asthma control. Clinical implications decision use inhaled steroids could be based trial. Different therapeutic strategies would established nonresponders.